Luna Musib
Neurology, Inc(US)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Cancer Treatment and Pharmacology, Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Melanoma and MAPK Pathways
Most-Cited Works
- → Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis(2018)651 cited
- → Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma(2010)510 cited
- → The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts(2005)436 cited
- → Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study(2014)294 cited
- → Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(2007)230 cited
- → Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer(2006)173 cited
- → A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors(2016)167 cited
- → A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas(2010)109 cited
- → Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas(2005)96 cited
- → Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors(2019)88 cited